Showing results (1091-1100 of 1,132) with videos related to
Sort By:
Pageof 114
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort StudyFrédéric Pouliot, Fred Saad, Etienne Rousseau, et al.The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.The Journal of Urology|December 2, 2024
Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause MortalityAnita Robert, Ranjeeta Mallick, Daniel I McIsaac, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical CharacterizationJ Brad Shotwell, Subramanian Baskaran, Pek Chong, et al.Nature Genetics|March 1, 1997
Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1R G Lafrenière, D L Rochefort, N Chrétien, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 21, 2025
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, et al.Leukemia|April 15, 2018
Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemiaMelissa A Burns, Zi Wei Liao, Natsuko Yamagata, et al.Biological Psychiatry|November 13, 2012
Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activityJerri M Rook, Meredith J Noetzel, Wendy A Pouliot, et al.The Lancet. Oncology|August 17, 2023
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trialMustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, et al.Plos One|November 14, 2019
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemiaGayle P Pouliot, James Degar, Laura Hinze, et al.Pageof 114